Verona Pharma Plc ADR (NASDAQ:VRNA)’s traded shares stood at 0.48 million during the latest session, with the company’s beta value hitting 0.45. At the last check today, the stock’s price was $31.11, to imply an increase of 8.36% or $2.4 in intraday trading. The VRNA share’s 52-week high remains $30.73, putting it 1.22% up since that peak but still an impressive 63.39% since price per share fell to its 52-week low of $11.39. The company has a valuation of $2.52B, with an average of 0.8 million shares in intraday trading volume over the past 10 days and average of 1.18 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Verona Pharma Plc ADR (VRNA), translating to a mean rating of 1.00. Of 7 analyst(s) looking at the stock, 0 analyst(s) give VRNA a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 7 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.5.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Verona Pharma Plc ADR (NASDAQ:VRNA) trade information
After registering a 8.36% upside in the latest session, Verona Pharma Plc ADR (VRNA) has traded red over the past five days. The 5-day price performance for the stock is 12.55%, and 13.05% over 30 days. With these gigs, the year-to-date price performance is 56.49%. Short interest in Verona Pharma Plc ADR (NASDAQ:VRNA) saw shorts transact 8.85 million shares and set a 7.11 days time to cover.
The extremes give us $26 and $38 for target low and target high price respectively. As such, VRNA has been trading -22.15% off suggested target high and 16.43% from its likely low.
Verona Pharma Plc ADR (VRNA) estimates and forecasts
Looking at statistics comparing Verona Pharma Plc ADR share performance against respective industry, we note that the company has underperformed competitors. Verona Pharma Plc ADR (VRNA) shares are 88.09% up over the last 6 months, with its year-to-date growth rate lower than industry average at -187.50% against 17.60%. Revenue is forecast to shrink -177.80% this quarter before falling -150.00% for the next one.
Revenue forecast for the current quarter as set by 6 analysts is 1.96M. Meanwhile, for the current quarter, a total of 6 analyst(s) estimate revenue growth to 4.99M.
VRNA Dividends
Verona Pharma Plc ADR has its next earnings report out on 2024-Aug-08. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Verona Pharma Plc ADR (NASDAQ:VRNA)’s Major holders
Verona Pharma Plc ADR insiders hold 3.16% of total outstanding shares, with institutional holders owning 91.83% of the shares at 94.82% float percentage. In total, 91.83% institutions holds shares in the company, led by RA CAPITAL MANAGEMENT, L.P. As of 2024-06-30, the company held over 7.63 million shares (or 9.4566% of shares), all amounting to roughly $110.37 million.
The next major institution holding the largest number of shares is NEA MANAGEMENT COMPANY, LLC with 5.58 million shares, or about 6.9193% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $80.76 million.
We also have Federated Hermes Kaufmann Fund and Federated Hermes Kaufmann Small Cap Fund as the top two Mutual Funds with the largest holdings of the Verona Pharma Plc ADR (VRNA) shares. Going by data provided on Jul 31, 2024, Federated Hermes Kaufmann Fund holds roughly 1.15 shares. This is just over 1.41% of the total shares, with a market valuation of $36.19 million. Data from the same date shows that the other fund manager holds a little less at 990.0, or 1.22% of the shares, all valued at about 31.29 million.
